Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Prescribing information can be found at the bottom of the page

Pfizer has a strong portfolio in licensed products for the treatment of pneumonia, including ZAVICEFTA® (ceftazidime and avibactam) and ZINFORO® (ceftaroline fosamil)*†1,2

Zavicefta® is indicated for the treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)
Zinforo® is indicated for the treatment of community acquired pneumonia (CAP) in neonates, infants, children, adolescents and adults2

Community Acquired Pneumonia (CAP)

When there’s no time to wait, evidence supports the use of Zinforo® in your CAP patients:

  • Fifth-generation cephalosporin with coverage against key causative pathogens in post-influenza CAP3,4
  • High clinical cure rates and rapid-response at Day 4 in CAP, including in complex patients with comorbidities5,6
  • Relatively low protein binding (20%) and using data comparing protein binding with rate of penetration to the site of infection, would be predicted to have a rapid penetration rate7,8
  • Established safety and tolerability profile consistent with other cephalosporins5
  • Simple dosing for the majority of patients, with a flexible 5-60 minute infusion time and no dosage adjustment required for most elderly patients and those with mild renal impairment or hepatic impairmentβ2

To access the details of clinical trial output, and practical use of Zinforo follow this link.


Access a number of videos from your colleagues sharing their experience on management of pneumonia and practical case studies

Challenges in the treatment of Community Acquired Pneumonia

Antoni Torres, Professor of Pulmonology and Respiratory Critical Care Medicine at University of Barcelona, Spain. 



Watch video

Hospital Acquired Pneumonia (HAP)/Ventilator Acquired Pneumonia (VAP)

The efficacy and safety profile of Zavicefta® make it a much-needed option for physicians faced with the challenge of treating hospitalised patients with HAP/VAP caused by suspected or confirmed resistant, aerobic Gram-negative bacteria, where the consequences of antibiotic failure can be devastating1,9,11,12

  • Zavicefta is as effective as a carbapenem in hospitalised patients with aerobic Gram-negative HAP, including VAP9,10
  • Zavicefta has an established safety and tolerability profile consistent with both cephalosporins and carbapenems9,13-15

To access the details of clinical trial output, and practical use of Zavicefta follow this link.


The three main challenges from Professor Torres in his experience in diagnosis and treatment of HAP/VAP nosocomial infections

Antoni Torres, Professor of Pulmonology and Respiratory Critical Care Medicine at University of Barcelona, Spain. 

Watch video

CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; VAP, ventilator associated pneumonia. 

**Zavicefta is indicated for treatment of complicated urinary tract infections, including pyelonephritis; complicated intra-abdominal infections; and hospital-acquired pneumonia, including ventilator-associated pneumonia infections in adults and paediatric patients aged 3 months and older. 
Zavicefta is also indicated for the treatment of adult patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.1
†Zinforo® is indicated for the treatment of patients with complicated skin and soft tissue infections and community-acquired pneumonia.2
‡Applies only for standard dose regimens in adults and children from 2 months of age, including patients with renal impairment. For patients with supranormal renal clearance receiving the standard dose, an infusion time of 60 minutes may be preferable. Prolonging the infusion duration may also help to manage infusion-related reactions (e.g. phlebitis). Infusion times of <60 minutes are based on PK/PD analyses only.1
βDosage adjustment required for patients with moderate or severe renal impairment (CrCl ≤50 mL/min).1


  1. ZAVICEFTA. Summary of Product Characteristics 
  2. ZINFORO. Summary of Product Characteristics
  3. Joseph C, et al. Influenza Other Respir Virus 2013;7:105-13
  4. Laudano JB. J Antimicrob Chemother 2011;66:iii11-18
  5. File TM, et al. Clin Infect Dis 2010;51:1395-405
  6. Eckburg P, et al. Infect Dis Clin Pract 2012;20:254-60. 
  7. Drusano GL, et al. J Antimicrob Chemother 2011;66:iii61-7
  8. Riccobene TA, et al. Antimicrob Agents Chemother 2016;60:5849-57
  9. Torres A, et al. Lancet Infect Dis 2018;18:285-95
  10. Torres A, et al. Open Forum Infect Dis 2019;6:ofz149;25
  11. Bonine NG, et al. Am J Med Sci 2018;357:103-10
  12. Raman G, et al. BMC Infect Dis 2015;15:395
  13. Mazuski JE, et al. Clin Infect Dis 2016;62:1380-9;26
  14. Carmeli Y, et al. Lancet Infect Dis 2016;16:661-3
  15. Wagenlehner FM, et al. Clin Infect Dis 2016;63:754-62

Prescribing Information
Click here to access the Prescribing Information for Zavicefta, Zinforo and Meronem